Breast Cancer

Researchers found that expression of the vitamin D receptor protein may help protect against aggressive forms of breast cancer.

A recent study found that radiologists differ in their interpretation of whether a woman has dense breasts based on mammography.

Results from a long-term study indicated that undergoing fertility treatment with in vitro fertilization did not increase women’s risk for breast cancer compared with women in the general population.

A triplet regimen including paclitaxel, capecitabine, and bevacizumab showed efficacy and safety in women with advanced triple-negative breast cancer.

A meta-analysis found that a Mediterranean diet with no limits on fat intake may reduce the incidence of breast cancer, as well as several other outcomes, compared to other diets.

Adding neratinib to standard paclitaxel chemotherapy appears to be associated with a better pathological complete response rate than chemotherapy plus trastuzumab.

Acupressure, a technique derived from acupuncture, helped improve sleep and relieved chronic fatigue experienced by women treated for breast cancer.

A 40-year-old woman noted a large mass in her right breast. A diagnostic mammogram and ultrasound confirmed a 3.4-cm mass with associated microcalcifications.

Researchers from the University of Michigan have developed new technology to separate aggressive stage 0 breast cancer from nonaggressive forms.

The combination of everolimus and exemestane was deemed generally tolerable with a manageable safety profile in women with advanced HR-positive/HER2-negative breast cancer.

Results of two studies taken from the I-SPY 2 trial showed that the use of adaptive randomization in a phase II trial was able to successfully identify agents that would be most effective at treating certain molecular subtypes of breast cancer

Researchers have uncovered a potential role of the bacteria found within breast tissue in the prevention and progression of breast cancer.

About 1 in every 5 older women who underwent treatment for early-stage breast cancer experienced a functional decline and/or died within 1 year of initiating treatment.

Researchers at Mount Sinai have made a crucial discovery in breast cancer by identifying a protein called CBX8, which promotes tumor growth.

A new combination therapy is showing promise for treating advanced solid tumors and may especially be beneficial in patients with recurrent or metastatic triple-negative breast cancer.

Maintenance therapy with low-dose cyclophosphamide and methotrexate in women with hormone receptor-negative early breast cancer did not improve disease-free survival.

A 34-year-old, gravida 2, para 1, previously healthy African-American woman presented with a right breast mass on self-examination in the second trimester of pregnancy.

As a collaborative effort of several cancer centers throughout the United States, teams of researchers have completed the first large-scale proteogenomic study of breast cancer.

Among breast cancer survivors, black women are far less likely to receive BRCA testing and preventive surgery than white or Hispanic women.

OPT-822/821 vaccination did not show any improvement in progression-free survival as maintenance therapy compared with placebo for metastatic breast cancer. But in those patients who had an immune response, the vaccine did appear to show activity.

Heavily pretreated women with metastatic breast cancer had significant improvements in progression-free survival and overall response rate when treated with the combination of utidelone plus capecitabine compared with capecitabine alone.

Postmenopausal women with early breast cancer benefit from extending AI therapy with letrozole from 5 to 10 years, and show no worsening of quality of life.

Directly engaging and recruiting patients online using social media will allow broader participation in cancer genomics research and hasten clinical advances.

The investigational biosimilar MYL-1401O has comparable efficacy and safety to the FDA-approved trastuzumab in metastatic HER2-positive breast cancer.

ESR1 mutations, which are believed to convey aromatase inhibitors (AIs) resistance in ER-positive, metastatic breast cancer, are not associated with tumor resistance to fulvestrant.